HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients

Sandra R. Reynolds, Esteban Celis, Alessandro Sette, Ruth Oratz, Richard L. Shapiro, Dean Johnston, Marilena Fotino, Jean Claude Bystryn

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

An important element in melanoma vaccine construction is to identify peptides from melanoma-associated Ags that have immunogenic potential in humans and are recognized by CD8+ T cells in vivo. To identify such peptides, we evaluated HLA-A*02+ melanoma patients immunized to a polyvalent vaccine containing multiple Ags, including MAGE-3, Melan-A/MART- 1, gp100, tyrosinase, melanocortin receptor (MC1R), and dopachrome tautomerase (TRP-2). Using a filter spot assay, we measured peripheral blood CD8+ T cell responses, before and after immunization, to a panel of 45 HLA- A*0201-restricted peptides derived from these Ags. The peptides were selected for immunogenic potential based on their strong binding affinity in vitro to HLAA*0201. Vaccine treatment induced peptide-specific CD8+ T cell responses to 22 (47.8%) of the peptides. The most striking finding was the HLA-independent heterogeneity of responses to both peptides and Ags. All responding patients reacted to different combination of peptides and Ags even though the responding patients were all A*0201+ and the peptides were all A*0201-restricted. From 9 to 27% of patients developed a CD8+ T cell response to at least one peptide from each Ag, but no more than 3 (14%) reacted to the same peptide from the same Ag. This heterogeneity of responses to individual peptides and Ags in patients with the same haplotype points to the need to construct vaccines of multiple peptides or Ags to maximize the proportion of responding patients.

Original languageEnglish (US)
Pages (from-to)6970-6976
Number of pages7
JournalJournal of Immunology
Volume161
Issue number12
StatePublished - Dec 15 1998
Externally publishedYes

Fingerprint

MART-1 Antigen
Monophenol Monooxygenase
Melanoma
Vaccines
T-Lymphocytes
Peptides
Melanocortin Receptors
Subunit Vaccines
HLA-A Antigens
Haplotypes

ASJC Scopus subject areas

  • Immunology

Cite this

HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. / Reynolds, Sandra R.; Celis, Esteban; Sette, Alessandro; Oratz, Ruth; Shapiro, Richard L.; Johnston, Dean; Fotino, Marilena; Bystryn, Jean Claude.

In: Journal of Immunology, Vol. 161, No. 12, 15.12.1998, p. 6970-6976.

Research output: Contribution to journalArticle

Reynolds, SR, Celis, E, Sette, A, Oratz, R, Shapiro, RL, Johnston, D, Fotino, M & Bystryn, JC 1998, 'HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients', Journal of Immunology, vol. 161, no. 12, pp. 6970-6976.
Reynolds, Sandra R. ; Celis, Esteban ; Sette, Alessandro ; Oratz, Ruth ; Shapiro, Richard L. ; Johnston, Dean ; Fotino, Marilena ; Bystryn, Jean Claude. / HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. In: Journal of Immunology. 1998 ; Vol. 161, No. 12. pp. 6970-6976.
@article{15b15348c7ea478e9c2196b0e2aabe86,
title = "HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients",
abstract = "An important element in melanoma vaccine construction is to identify peptides from melanoma-associated Ags that have immunogenic potential in humans and are recognized by CD8+ T cells in vivo. To identify such peptides, we evaluated HLA-A*02+ melanoma patients immunized to a polyvalent vaccine containing multiple Ags, including MAGE-3, Melan-A/MART- 1, gp100, tyrosinase, melanocortin receptor (MC1R), and dopachrome tautomerase (TRP-2). Using a filter spot assay, we measured peripheral blood CD8+ T cell responses, before and after immunization, to a panel of 45 HLA- A*0201-restricted peptides derived from these Ags. The peptides were selected for immunogenic potential based on their strong binding affinity in vitro to HLAA*0201. Vaccine treatment induced peptide-specific CD8+ T cell responses to 22 (47.8{\%}) of the peptides. The most striking finding was the HLA-independent heterogeneity of responses to both peptides and Ags. All responding patients reacted to different combination of peptides and Ags even though the responding patients were all A*0201+ and the peptides were all A*0201-restricted. From 9 to 27{\%} of patients developed a CD8+ T cell response to at least one peptide from each Ag, but no more than 3 (14{\%}) reacted to the same peptide from the same Ag. This heterogeneity of responses to individual peptides and Ags in patients with the same haplotype points to the need to construct vaccines of multiple peptides or Ags to maximize the proportion of responding patients.",
author = "Reynolds, {Sandra R.} and Esteban Celis and Alessandro Sette and Ruth Oratz and Shapiro, {Richard L.} and Dean Johnston and Marilena Fotino and Bystryn, {Jean Claude}",
year = "1998",
month = "12",
day = "15",
language = "English (US)",
volume = "161",
pages = "6970--6976",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "12",

}

TY - JOUR

T1 - HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients

AU - Reynolds, Sandra R.

AU - Celis, Esteban

AU - Sette, Alessandro

AU - Oratz, Ruth

AU - Shapiro, Richard L.

AU - Johnston, Dean

AU - Fotino, Marilena

AU - Bystryn, Jean Claude

PY - 1998/12/15

Y1 - 1998/12/15

N2 - An important element in melanoma vaccine construction is to identify peptides from melanoma-associated Ags that have immunogenic potential in humans and are recognized by CD8+ T cells in vivo. To identify such peptides, we evaluated HLA-A*02+ melanoma patients immunized to a polyvalent vaccine containing multiple Ags, including MAGE-3, Melan-A/MART- 1, gp100, tyrosinase, melanocortin receptor (MC1R), and dopachrome tautomerase (TRP-2). Using a filter spot assay, we measured peripheral blood CD8+ T cell responses, before and after immunization, to a panel of 45 HLA- A*0201-restricted peptides derived from these Ags. The peptides were selected for immunogenic potential based on their strong binding affinity in vitro to HLAA*0201. Vaccine treatment induced peptide-specific CD8+ T cell responses to 22 (47.8%) of the peptides. The most striking finding was the HLA-independent heterogeneity of responses to both peptides and Ags. All responding patients reacted to different combination of peptides and Ags even though the responding patients were all A*0201+ and the peptides were all A*0201-restricted. From 9 to 27% of patients developed a CD8+ T cell response to at least one peptide from each Ag, but no more than 3 (14%) reacted to the same peptide from the same Ag. This heterogeneity of responses to individual peptides and Ags in patients with the same haplotype points to the need to construct vaccines of multiple peptides or Ags to maximize the proportion of responding patients.

AB - An important element in melanoma vaccine construction is to identify peptides from melanoma-associated Ags that have immunogenic potential in humans and are recognized by CD8+ T cells in vivo. To identify such peptides, we evaluated HLA-A*02+ melanoma patients immunized to a polyvalent vaccine containing multiple Ags, including MAGE-3, Melan-A/MART- 1, gp100, tyrosinase, melanocortin receptor (MC1R), and dopachrome tautomerase (TRP-2). Using a filter spot assay, we measured peripheral blood CD8+ T cell responses, before and after immunization, to a panel of 45 HLA- A*0201-restricted peptides derived from these Ags. The peptides were selected for immunogenic potential based on their strong binding affinity in vitro to HLAA*0201. Vaccine treatment induced peptide-specific CD8+ T cell responses to 22 (47.8%) of the peptides. The most striking finding was the HLA-independent heterogeneity of responses to both peptides and Ags. All responding patients reacted to different combination of peptides and Ags even though the responding patients were all A*0201+ and the peptides were all A*0201-restricted. From 9 to 27% of patients developed a CD8+ T cell response to at least one peptide from each Ag, but no more than 3 (14%) reacted to the same peptide from the same Ag. This heterogeneity of responses to individual peptides and Ags in patients with the same haplotype points to the need to construct vaccines of multiple peptides or Ags to maximize the proportion of responding patients.

UR - http://www.scopus.com/inward/record.url?scp=0032534598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032534598&partnerID=8YFLogxK

M3 - Article

VL - 161

SP - 6970

EP - 6976

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 12

ER -